Clinical trial NCT06682806: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Official title: A Phase 2, Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Advanced Solid Tumor
Esophageal Cancer
Metastatic Solid Tumor
Non-small Cell Lung Cancers
SMARCA4 Gene Mutation
Keywords: Advanced Solid Tumors
BRG1
BRM
Esophageal Cancer
Metastatic Solid Tumors
Non-Small Cell Lung Cancers
NSCLC
PRT3789
Pembrolizumab
Keytruda®
SMARCA2 Degrader
SMARCA4
Lead sponsor: Prelude Therapeutics
Sponsor class: INDUSTRY
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2024-11-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with advanced, recurrent or metastatic solid tumors with a SMARCA4 mutation.

Detailed description: This is an open-label, multi-center Phase 2 study of PRT 3789, a first-in-class SMARCA2 targeted protein degrader, in combination with pembrolizumab, a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, evaluating patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation. This study consists of 2 parts. Part 1 is a safety run-in and will establish the dose of PRT3789 to be used in combination with pembrolizumab in the main study (Part 2). For Part 2 (Main study) primary endpoints are ORR (defined as the proportion of patients with a confirmed best overall response of either complete response or partial response) and duration of response per investigator assessment per RECIST v1.1.

Approximately 46 to 60 patients will be enrolled in Part 1 and Part 2 based on the dose of PRT3789 selected/cleared during the safety run-in.

Eligibility criteria: Inclusion Criteria:

* Patients who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations and other study procedures, including providing informed consent.
* Patients must either progress on standard of care therapy or be ineligible for standard of care therapy in order to be eligible for enrollment on the study.
* Part 1 Safety Run-in: Patients with advanced, recurrent, or metastatic histologically or cytologically confirmed solid tumor malignancy and any mutation of SMARCA4 detected by next generation sequencing in tumor tissue or blood, or absence of SMARCA4 protein (BRG1). Part 2 Main Study: Patients with advanced, recurrent, or metastatic histologically confirmed esophageal cancer or NSCLC and have a deleterious SMARCA4 mutation, or absence of SMARCA4 protein (BRG1) detected by immunohistochemistry in tumor tissue using a clinically validated laboratory test.
* Part 1 Run-in: Measurable or non-measurable (but evaluable) disease per RECIST v1.1 as assessed by the local site investigator/radiologist. Part 2 Main Study: Measurable disease per RECIST v1.1 as assessed by the local site investigator/radiologist. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
* Willingness and ability to provide tumor tissue (i.e., archived or fresh tumor biopsy if archived tumor tissue is unavailable)
* Adequately controlled blood pressure with or without antihypertensive medications.
* Patients with HIV must have well-controlled HIV on antiretroviral therapy.
* Adequate organ function

Exclusion Criteria:

* Patients who have adverse events due to previous anticancer therapies and/or complications from prior surgical intervention must have recovered to ≤ Grade 1 or baseline before starting study treatment. Patients with endocrine-related AEs who are adequately treated with hormone replacement or patients who have ≤ Grade 2 neuropathy are eligible.
* Other acute or chronic medical or psychiatric conditions that would make the patient inappropriate for entry into this study.
* Patients with solid tumors with a known concomitant SMARCA2 mutation or loss of protein expression.
* Uncontrolled or symptomatic central nervous system (CNS) metastases or leptomeningeal disease and/or carcinomatous meningitis).
* History of or current (noninfectious) pneumonitis/interstitial lung disease
* Diagnosis of immunodeficiency disease/disorder.
* Known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Patients who received prior treatment with an agent directed to a stimulatory or co-inhibitory T-cell receptor.
* Currently taking a strong or moderate CYP3A4 inhibitor or inducer and St. John's Wort and are unable to discontinue use within 15 days of the first dose of study treatment.
* Receipt of any targeted therapy directed against BRM/BRG1 (SMARCA2/SMARCA4).
* Pregnant or breastfeeding or plan to become pregnant during the duration of the study.

Primary outcomes:
measure: Safety and tolerability of PRT3789 in combination with pembrolizumab as measured by incidence of DLTs (Part 1)
timeFrame: Baseline through completion of study, an average of 2 years
measure: Safety and tolerability of PRT3789 in combination with pembrolizumab as measured by incidence and severity of AEs according to NCI CTCAE (Part 1)
timeFrame: Baseline through study completion, an average of 2 years
measure: Efficacy of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic esophageal or NSCLC and deleterious SMARCA4 mutation: Objective Response Rate (Part 2)
timeFrame: Baseline through study completion, an average of 2 years
measure: Efficacy of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic esophageal or NSCLC and deleterious SMARCA4 mutation: Duration of Response (Part 2)
timeFrame: Baseline through study completion, an average of 2 years
Secondary outcomes:
measure: Efficacy of PRT3789 in combination with pembrolizumab: Objective Response Rate (Part 1)
timeFrame: Baseline through study completion, an average of 2 years
measure: Efficacy of PRT3789 in combination with pembrolizumab: Duration of Response (Part 1)
timeFrame: Baseline through study completion, an average of 2 years
measure: Efficacy of PRT3789 in combination with pembrolizumab (part 1 and part 2): Clinical Benefit Response
timeFrame: Baseline through study completion, an average of 2 years
measure: Efficacy of PRT3789 in combination with pembrolizumab (part 1 and part 2): Progression-Free Survival
timeFrame: Baseline through study completion, an average of 2 years
measure: Efficacy of PRT3789 in combination with pembrolizumab (part 1 and part 2): Overall Survival
timeFrame: Baseline through study completion, an average of 2 years
measure: Safety and tolerability of PRT3789 in combination with pembrolizumab as measured by AEs according to NCI CTCAE
timeFrame: Baseline through study completion, an average of 2 years
measure: Safety and tolerability of PRT3789 in combination with pembrolizumab: as measured by key clinical laboratory parameters
timeFrame: Baseline through study completion, an average of 2 years
measure: Safety and tolerability as measured by incidence of dose modification due to AEs
timeFrame: Baseline through study completion, an average of 2 years
measure: PK profile of PRT3789 in combination with pembrolizumab: Maximum observed plasma concentration: Maximum observed plasma concentration
timeFrame: Baseline through study completion, an average of 2 years
measure: PK profile of PRT3789 in combination with pembrolizumab: Area under the curve
timeFrame: Baseline through study completion, an average of 2 years
measure: PK profile of PRT3789 in combination with pembrolizumab: Time of maximum concentration (Tmax) and half-life (T1/2)
timeFrame: Baseline through study completion, an average of 2 years
Other outcomes:
Locations:
city: West Palm Beach
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: Hackensack
country: United States
facility: John Theurer Cancer Center at Hackensack University Medical Center
state: New Jersey
city: Nashville
country: United States
facility: SCRI Oncology Partners
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research
state: Tennessee
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
city: Barcelona
country: Spain
facility: IOB - Next Oncology - Hospital Quironsalud Barcelona
city: Barcelona
country: Spain
facility: START Barcelona - HM Nou Delfos
city: Madrid
country: Spain
facility: Hospital Universitario Fundacion Jimenez Diaz - Servicio de Oncologia
Study officials:
References: